重症患者急性肺损伤:肌动蛋白清除剂凝溶胶蛋白信号提示迁延性呼吸衰竭
该研究为PASS随机临床试验的亚组队列研究,纳入746例需要机械通气的危重症呼吸衰竭患者,主要终点为28天内成功脱机。采用多变量Cox回归校正年龄、脓毒症、PaO2/FiO2比值等已知及疑似迁延性呼吸衰竭预测因素。结果显示,在内科患者中,基线凝溶胶蛋白低于第25百分位独立预测28天内成功脱机几率降低40%(HR 0.60,95%CI 0.46-0.79,P=0.0002),外科患者中未显示预测作用。低凝溶胶蛋白水平预测内科和外科患者第14天「存活且离开ICU」的几率(HR 0.69,95%CI 0.54-0.89,P=0.004),但未预测28天死亡率。
要点
- 内科ICU需要机械通气的呼吸衰竭患者中,基线凝溶胶蛋白低于第25百分位独立预测28天内成功脱机几率降低40%(HR 0.60,95%CI 0.46-0.79,P=0.0002)。
- 外科患者中,基线凝溶胶蛋白低于第25百分位未预测28天内成功脱机。
- 低凝溶胶蛋白水平预测内科和外科患者第14天「存活且离开ICU」的几率降低(HR 0.69,95%CI 0.54-0.89,P=0.004)。
- 凝溶胶蛋白水平未预测内科或外科患者的28天死亡率。
- 作者认为,该发现对早期识别需要个体化干预以防止急性呼吸衰竭不良肺部预后的患者有意义。
适用人群与场景
- 来自PASS随机临床试验的746例需要机械通气的危重症呼吸衰竭患者,分为内科患者和外科患者。
研究设计与关键结果
- 研究类型为PASS随机临床试验的亚组队列研究,纳入746例需要机械通气的危重症呼吸衰竭患者,主要终点为28天内成功脱机,随访完整。
- 采用多变量Cox回归校正年龄、脓毒症、PaO2/FiO2比值及其他已知和疑似迁延性呼吸衰竭预测因素。
- 内科患者中,基线凝溶胶蛋白低于第25百分位独立预测28天内成功脱机几率降低40%(HR 0.60,95%CI 0.46-0.79,P=0.0002);外科患者中未预测该终点。
- 低凝溶胶蛋白水平预测内科和外科患者第14天「存活且离开ICU」的几率降低(HR 0.69,95%CI 0.54-0.89,P=0.004)。
- 凝溶胶蛋白水平未预测内科或外科患者的28天死亡率。
证据类型、等级与局限
- 证据类型:随机临床试验(PASS)的亚组队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在内科ICU需要机械通气的呼吸衰竭患者中,基线血浆凝溶胶蛋白低于第25百分位提示28天内成功脱机几率降低(HR 0.60,95%CI 0.46-0.79),作者认为该发现对早期识别需要个体化干预以防止急性呼吸衰竭不良肺部预后的患者有意义。
- 在外科ICU患者中,基线凝溶胶蛋白低于第25百分位未预测28天内成功脱机。
- 低凝溶胶蛋白水平预测内科和外科患者第14天「存活且离开ICU」的几率降低(HR 0.69,95%CI 0.54-0.89),但未预测28天死亡率。
指南或共识出处
- Procalcitonin And Survival Study (PASS),Clinicaltrials.gov ID: NCT00271752,首次注册日期2006年1月1日。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Gelsolin is an actin-scavenger controlling the tissue damage from actin in the blood. Gelsolin levels in circulation drops when tissue damage and corresponding actin release is pronounced due to catabolic conditions. The purpose of this study was to determine if low plasma gelsolin independently predicts a reduced chance of weaning from ventilator-demanding respiratory failure in critically ill patients within 28 days from admission.
RESULTS: This cohort study included 746 critically ill patients with ventilator-demanding respiratory failure from the randomized clinical trial, "Procalcitonin And Survival Study (PASS)." Primary end point was successful weaning from mechanical ventilation within 28 days. We used multivariable Cox regression adjusted for age, sepsis, PaO2/FiO2 ratio and other known and suspected predictors of persistent respiratory failure. Follow-up was complete.For medical patients, baseline-gelsolin below the 25th percentile independently predicted a 40% lower chance of successful weaning within 28 days (HR 0.60, 95% CI 0.46-0.79, P = 0.0002); among surgical patients this end point was not predicted. Low gelsolin levels predicted chance of being "alive and out of intensive care at day 14" for both medical and surgical patients (HR 0.69, 95% CI 0.54-0.89, P = 0.004). Gelsolin levels did not predict 28 day mortality for surgical or medical patients.
CONCLUSIONS: Low levels of serum gelsolin independently predict a decreased chance of successful weaning from ventilator within 28 days among medical intensive care patients. This finding has implications for identifying patients who need individualized intervention early in intensive care course to prevent unfavorable lung prognosis in acute respiratory failure.
TRIAL REGISTRATION: This is a substudy to the PASS, Clinicaltrials.gov ID: NCT00271752, first registered January 1, 2006.
参考来源
- Holm FS, Sivapalan P, Seersholm N, et al. Acute Lung Injury in Critically Ill Patients: Actin-Scavenger Gelsolin Signals Prolonged Respiratory Failure. Shock. 2019. PMID: 30339635. doi:10.1097/SHK.0000000000001279
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。